98%
921
2 minutes
20
Objective: In recent years, the noninvasive serological scoring system has become a research hotspot in predicting hepatic fibrosis and has achieved good results. However, it has rarely been applied to the prediction of oesophageal varices. The aim of the study was to evaluate the predictive value of the four following scoring systems in cirrhosis combined with oesophageal varices: aspartate and platelet ratio index (APRI), aspartate aminotransferase-alanine aminotransferase ratio (AAR), FIB-4, and S index.
Methods: A total of 153 patients with cirrhosis were categorized into groups with or without oesophageal varices. In addition, cirrhosis patients with oesophageal varices were further divided into mild, moderate, and severe grades. The rank sum test was used to compare the significant differences of APRI, AAR, FIB-4, and S index between the two groups of cirrhosis patients with or without oesophageal varices. A ROC curve was generated to compare the area under the curve of the three groups and to obtain the corresponding optimal prediction value. Moreover, multivariate logistic regression analysis was employed to assess the predictive factors for cirrhosis combined with oesophageal varices.
Results: 44 patients had no oesophageal varices and 108 patients had oesophageal varices. Of the 108 patients with oesophageal varices, 43 were mild, 32 were moderate, and 33 were severe. The rank sum test indicated that the APRI, FIB-4, and S index were statistically significant between two groups ( < 0.05), while no significant difference was detected in terms of AAR between the two groups ( > 0.05). In addition, all four scoring systems were statistically significant between nonoesophageal varices group and severe oesophageal varices group ( < 0.05). In the ROC curve of oesophageal varices, the AUC values of APRI, FIB-4, and S index for predicting oesophageal varices were 0.681, 0642, and 0.673, respectively. However, in the ROC curve of severe oesophageal varices, the AUC values of APRI, AAR, FIB-4, and S index were 0.729, 0.648, 0.673, and 0.695, respectively. Multivariate logistic regression analysis indicated that APRI and FIB-4 were predictors of disease progression ( < 0.05).
Conclusion: AAR harboured a poor predictive value for oesophageal varices, APRI can be used as a reference index for the prediction of severe oesophageal varices, and the S index harboured potential value in predicting the degree of progression of cirrhosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112226 | PMC |
http://dx.doi.org/10.1155/2018/7671508 | DOI Listing |
JGH Open
September 2025
Department of Genomic Medicine, Division of Biochemistry, Molecular Biology, and Nutrition University Hospital of Nancy Nancy France.
Introduction: Cirrhosis progresses from compensated to decompensated phases, often marked by portal hypertension and complications like ascites, variceal hemorrhage, and hepatic encephalopathy. The ammonia-to-urea (A-to-U) ratio, reflecting urea cycle efficiency, may offer superior diagnostic performance compared to plasma ammonia levels alone. This study compared the diagnostic accuracy of the A-to-U ratio and plasma ammonia levels for identifying portal hypertension.
View Article and Find Full Text PDFJHEP Rep
October 2025
Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
Background & Aims: Conflicting evidence exists on hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B (CHB) receiving tenofovir entecavir. We assessed the impacts of the two drugs on the clinical trajectory of CHB at a population level.
Methods: We conducted a retrospective nationwide cohort study using data from Taiwan's National Health Insurance Research Database, including 55,885 patients with CHB who were treatment-naïve aged 30-75 years receiving tenofovir (n = 17,137) or entecavir (n = 38,748) monotherapy for ≥3 months between November 2009 and December 2020, and followed until December 2022.
Gastrointest Endosc
September 2025
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Far Eastern, Memorial Hospital, New Taipei City, Taiwan; Taiwan Association for the Study of Intestinal Diseases (TASID), Taoyuan City, Taiwan; College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
World J Methodol
December 2025
Department of Clinical Sciences, Lund University, Malmo 22100, Sweden.
Portal hypertension (PH) is a major complication of chronic liver disease, often leading to serious clinical consequences such as variceal bleeding, ascites, and splenomegaly. The current gold standard for PH diagnosis, namely, hepatic venous pressure gradient measurement, is invasive and not widely available. Transient elastography has emerged as a non-invasive alternative for assessing liver stiffness (LS), and recent studies have highlighted the potential role of splenic stiffness (SS) in evaluating PH severity.
View Article and Find Full Text PDFBMC Gastroenterol
September 2025
Faculty of Medicine, AL-Neelain University, Khartoum, Sudan.
Background: Upper gastrointestinal bleeding remains a significant medical emergency with considerable morbidity and mortality rates. Esophagogastroduodenoscopy is a key procedure because of its diagnostic and therapeutic value. Understanding the clinical picture as well as the expected endoscopic variations in the area can potentially improve fatal complications.
View Article and Find Full Text PDF